Filing Overview
Registrant: Happiness Biotech Group Limited; the request metadata identifies Paranovus Entertainment Technology Ltd., which does not match the registrant named in the filing. This Form 6-K reports unaudited results for the six months ended September 30, 2020, compared with the six months ended September 30, 2019. The company files annual reports on Form 20-F.
Financial Results and Liquidity
| Metric | Six months ended September 30, 2020 | Six months ended September 30, 2019 |
|---|---|---|
| Revenue | $21.9 million | $31.4 million |
| Gross profit | $9.6 million | $15.8 million |
| Gross margin | 43.8% | 50.5% |
| Operating income | $3.7 million | $9.8 million |
| Income before taxes | $3.9 million | $9.9 million |
| Net income | $3.2 million | $8.4 million |
| Net income attributable to the company | $3.2 million | $8.4 million |
| Net margin | 14.6% | 26.9% |
| Basic and diluted EPS | $0.13 | $0.37 |
| Operating cash flow | $8.6 million | $8.9 million |
Cash and cash equivalents were $43.8 million at September 30, 2020, versus $33.7 million at March 31, 2020. Current assets were $75.4 million and current liabilities were $5.9 million. Total liabilities were $5.9 million, including $2.4 million of short-term bank borrowings. The filing reports no commitments or contingencies. Total assets were $93.6 million and total equity was $87.7 million at September 30, 2020.
Net cash used in investing activities was $1.2 million, primarily for equipment purchases for new subsidiaries. Net cash provided by financing activities was $1.2 million, including approximately $2.1 million from new share issuance, partly offset by approximately $0.8 million of repayments to related parties. The net increase in cash was $10.1 million, including a $1.5 million favorable foreign-exchange effect.
Material Changes Versus Prior Period
- Revenue decreased $9.5 million, or 30.2%, primarily because of lower sales of Cordyceps mycelia, Ejiao solution, vitamins and dietary supplements, and American ginseng products.
- Gross profit decreased $6.2 million, and gross margin declined 6.7 percentage points to 43.8%, reflecting weaker retail demand, increased competition, and lower pricing.
- Operating income declined 62.4% to $3.7 million.
- Net income declined 62.2% to $3.2 million, while the effective income tax rate was 18.5%.
- Selling and marketing expense increased 3.0% to $3.7 million, primarily due to higher subsidies to experience stores.
- General and administrative expense increased 13.0% to $1.4 million, principally because of Cayman entity professional fees and related-party repayments.
- Research and development expense decreased 34.2% to $0.7 million because COVID-19 travel restrictions affected research staffing and the supply of research materials.
- Operating cash flow was broadly stable despite the decline in earnings, aided by a $9.2 million reduction in accounts receivable.
Business Developments, Outlook, and Risks
The company primarily manufactures and sells nutraceutical and dietary supplement products. As of September 30, 2020, it marketed approximately 32 products with “Blue Caps” approvals, through more than 200 distributors in 27 Chinese provinces and 30 experience stores.
New subsidiaries were established to expand into e-commerce, facial-mask sales, and new-media e-commerce and supply-chain integration. Happy Buy (Fujian) Internet Technology Co., Limited was incorporated in July 2020 to develop the e-commerce business. The company also established or invested in two 51%-owned subsidiaries during 2020.
On September 22, 2020, the company closed a private placement of 900,000 ordinary shares at $2.50 per share, generating $2.25 million of gross proceeds and $2.23 million of net proceeds.
On January 4, 2021, the company entered into agreements for a registered direct offering of up to 4.2 million ordinary shares. The first tranche covered 860,214 shares at $1.86 per share. Assuming all 4.2 million shares are sold at $1.86, gross proceeds would be $7.812 million before offering expenses. Proceeds are intended for e-commerce development, working capital, and capital expenditures. The offering was scheduled to expire July 4, 2021.
The filing provides no formal financial guidance. Key risks include declining demand in traditional nutrition products, competitive and pricing pressure, COVID-19-related operating and research disruptions, execution risk in the new e-commerce initiatives, foreign-exchange movements, and potential dilution from equity offerings. The financial information is unaudited and may change following year-end audit procedures.
Investor Verification Items
- Verify the issuer identity because the filing names Happiness Biotech Group Limited, while the request metadata names Paranovus Entertainment Technology Ltd.
- Confirm the final audited results and assess whether subsequent audit adjustments materially affect the unaudited figures.
- Review revenue trends, gross-margin pressure, and the company’s ability to restore demand and pricing for traditional supplement products.
- Assess the performance and funding requirements of the newly formed e-commerce subsidiaries.
- Confirm the actual completion, pricing, net proceeds, and use of proceeds of the registered direct offering.
- Monitor dilution from the private placement and registered direct offering, as well as the company’s short-term bank borrowings and related-party transactions.